Maria Papadaki1, Petr G Vikhorev1, Steven B Marston1, Andrew E Messer2. 1. National Heart and Lung Institute, Imperial College London, London W12 0NN, UK. 2. National Heart and Lung Institute, Imperial College London, London W12 0NN, UK a.messer@imperial.ac.uk.
Abstract
AIMS: Heart muscle contraction is regulated via the β-adrenergic response that leads to phosphorylation of Troponin I (TnI) at Ser22/23, which changes the Ca(2+) sensitivity of the cardiac myofilament. Mutations in thin filament proteins that cause dilated cardiomyopathy (DCM) and some mutations that cause hypertrophic cardiomyopathy (HCM) abolish the relationship between TnI phosphorylation and Ca(2+) sensitivity (uncoupling). Small molecule Ca(2+) sensitizers and Ca(2+) desensitizers that act upon troponin alter the Ca(2+) sensitivity of the thin filament, but their relationship with TnI phosphorylation has never been studied before. METHODS AND RESULTS: Quantitative in vitro motility assay showed that 30 µM EMD57033 and 100 µM Bepridil increase Ca(2+) sensitivity of phosphorylated cardiac thin filaments by 3.1- and 2.8-fold, respectively. Additionally they uncoupled Ca(2+) sensitivity from TnI phosphorylation, mimicking the effect of HCM mutations. Epigallocatechin-3-gallate (EGCG) decreased Ca(2+) sensitivity of phosphorylated and unphosphorylated wild-type thin filaments equally (by 2.15 ± 0.45- and 2.80 ± 0.48-fold, respectively), retaining the coupling. Moreover, EGCG also reduced Ca(2+) sensitivity of phosphorylated but not unphosphorylated thin filaments containing DCM and HCM-causing mutations; thus, the dependence of Ca(2+) sensitivity upon TnI phosphorylation of uncoupled mutant thin filaments was restored in every case. In single mouse heart myofibrils, EGCG reduced Ca(2+) sensitivity of force and kACT and also preserved coupling. Myofibrils from the ACTC E361G (DCM) mouse were uncoupled; EGCG reduced Ca(2+) sensitivity more for phosphorylated than for unphosphorylated myofibrils, thus restoring coupling. CONCLUSION: We conclude that it is possible to both mimic and reverse the pathological defects in troponin caused by cardiomyopathy mutations pharmacologically. Re-coupling by EGCG may be of potential therapeutic significance for treating cardiomyopathies. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Heart muscle contraction is regulated via the β-adrenergic response that leads to phosphorylation of Troponin I (TnI) at Ser22/23, which changes the Ca(2+) sensitivity of the cardiac myofilament. Mutations in thin filament proteins that cause dilated cardiomyopathy (DCM) and some mutations that cause hypertrophic cardiomyopathy (HCM) abolish the relationship between TnI phosphorylation and Ca(2+) sensitivity (uncoupling). Small molecule Ca(2+) sensitizers and Ca(2+) desensitizers that act upon troponin alter the Ca(2+) sensitivity of the thin filament, but their relationship with TnI phosphorylation has never been studied before. METHODS AND RESULTS: Quantitative in vitro motility assay showed that 30 µM EMD57033 and 100 µM Bepridil increase Ca(2+) sensitivity of phosphorylated cardiac thin filaments by 3.1- and 2.8-fold, respectively. Additionally they uncoupled Ca(2+) sensitivity from TnI phosphorylation, mimicking the effect of HCM mutations. Epigallocatechin-3-gallate (EGCG) decreased Ca(2+) sensitivity of phosphorylated and unphosphorylated wild-type thin filaments equally (by 2.15 ± 0.45- and 2.80 ± 0.48-fold, respectively), retaining the coupling. Moreover, EGCG also reduced Ca(2+) sensitivity of phosphorylated but not unphosphorylated thin filaments containing DCM and HCM-causing mutations; thus, the dependence of Ca(2+) sensitivity upon TnI phosphorylation of uncoupled mutant thin filaments was restored in every case. In single mouse heart myofibrils, EGCG reduced Ca(2+) sensitivity of force and kACT and also preserved coupling. Myofibrils from the ACTC E361G (DCM) mouse were uncoupled; EGCG reduced Ca(2+) sensitivity more for phosphorylated than for unphosphorylated myofibrils, thus restoring coupling. CONCLUSION: We conclude that it is possible to both mimic and reverse the pathological defects in troponin caused by cardiomyopathy mutations pharmacologically. Re-coupling by EGCG may be of potential therapeutic significance for treating cardiomyopathies. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Andrew E Messer; Clare E Gallon; William J McKenna; Cristobal G Dos Remedios; Steven B Marston Journal: Proteomics Clin Appl Date: 2009-10-13 Impact factor: 3.494
Authors: Christopher Semsarian; Imran Ahmad; Michael Giewat; Dimitrios Georgakopoulos; Joachim P Schmitt; Bradley K McConnell; Steven Reiken; Ulrike Mende; Andrew R Marks; David A Kass; Christine E Seidman; J G Seidman Journal: J Clin Invest Date: 2002-04 Impact factor: 14.808
Authors: Franz Baudenbacher; Tilmann Schober; Jose Renato Pinto; Veniamin Y Sidorov; Fredrick Hilliard; R John Solaro; James D Potter; Björn C Knollmann Journal: J Clin Invest Date: 2008-11-20 Impact factor: 14.808
Authors: Alexey V Dvornikov; Nikolai Smolin; Mengjie Zhang; Jody L Martin; Seth L Robia; Pieter P de Tombe Journal: J Biol Chem Date: 2016-08-24 Impact factor: 5.157
Authors: Maria Papadaki; Ronald J Holewinski; Samantha Beck Previs; Thomas G Martin; Marisa J Stachowski; Amy Li; Cheavar A Blair; Christine S Moravec; Jennifer E Van Eyk; Kenneth S Campbell; David M Warshaw; Jonathan A Kirk Journal: JCI Insight Date: 2018-10-18
Authors: Chad M Warren; Chehade N Karam; Beata M Wolska; Tomoyoshi Kobayashi; Pieter P de Tombe; Grace M Arteaga; J Martijn Bos; Michael J Ackerman; R John Solaro Journal: Circ Cardiovasc Genet Date: 2015-11-09
Authors: Marco L Alves; Chad M Warren; Jillian N Simon; Robert D Gaffin; Eric M Montminy; David F Wieczorek; R John Solaro; Beata M Wolska Journal: Cardiovasc Res Date: 2017-07-01 Impact factor: 10.787
Authors: Andrew E Messer; Christopher R Bayliss; Mohammed El-Mezgueldi; Charles S Redwood; Douglas G Ward; Man-Ching Leung; Maria Papadaki; Cristobal Dos Remedios; Steven B Marston Journal: Arch Biochem Biophys Date: 2016-03-29 Impact factor: 4.013